MarketCap
Prothena Corporation plc PRTA
$ 8.56
-2.62%
Facebook
X
Telegram
Prothena Corporation plc ROCE Ratio | PRTA
Annual ROCE Ratio Prothena Corporation plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -75.06 | -31.0 | -29.87 | -18.58 | 12.5 | -36.71 | -21.36 | -29.49 | -33.83 | -38.08 | -22.02 | -2.28 | -23.1 | -32.47 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.5 | -75.06 | -27.24 |
Quarterly ROCE Ratio Prothena Corporation plc
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.07 | -36.69 | -44.12 | -53.58 | -65.7 | -42.59 | -31.1 | -16.43 | -14.94 | -13.07 | -30.95 | -16.89 | -26.88 | -36.85 | -33.57 | -25.43 | -7.34 | 9.94 | 9.41 | 16.37 | 6.33 | -20.47 | -35.85 | -26.84 | -32.06 | -26.62 | -23.64 | -15.55 | -20.57 | -28.38 | -33.84 | -28.13 | -39.79 | -38.72 | -33.58 | -23.52 | -33.71 | -31.63 | -34.22 | -26.32 | -32.56 | -27.34 | -21.89 | -15.35 | -19.85 | -13.07 | -1.93 | 2.21 | -3.26 | -5.15 | -13.22 | -19.39 | -26.24 | -28.45 | -30.6 | -23.08 | -6.85 | -7.68 | -8.55 | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.37 | -65.7 | -22.51 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Nektar Therapeutics
NKTR
|
-155.96 | $ 37.82 | -0.01 % | $ 638 M |  USA |
 |
Vaccinex
VCNX
|
753.01 | - | -61.37 % | $ 654 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
63.22 | - | -19.68 % | $ 18.4 M |  Canada |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-82.2 | $ 1.05 | -3.24 % | $ 242 M | USA |
 |
Jounce Therapeutics
JNCE
|
-28.53 | - | - | $ 98.4 M | USA |
 |
Verona Pharma plc
VRNA
|
-35.83 | - | - | $ 69.7 B |  Britain |
 |
Corner Growth Acquisition Corp.
COOL
|
669.98 | - | -0.89 % | $ 114 M | USA |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-60.98 | $ 7.0 | -8.62 % | $ 471 B | Britain |
 |
Mersana Therapeutics
MRSN
|
-36.18 | - | - | $ 3.56 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-34.79 | - | - | $ 3.45 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-187.83 | - | - | $ 384 M | Britain |
 |
Genmab A/S
GMAB
|
31.74 | $ 54.08 | -3.08 % | $ 3.5 B |  Danmark |
 |
Allakos
ALLK
|
-155.07 | - | - | $ 28.6 M | USA |
 |
Timber Pharmaceuticals
TMBR
|
-367.47 | - | - | $ 717 K | USA |
 |
Immuron Limited
IMRN
|
-65.47 | $ 0.9 | 2.27 % | $ 208 M |  Australia |
 |
G1 Therapeutics
GTHX
|
-111.7 | - | - | $ 370 M | USA |
 |
Amryt Pharma plc
AMYT
|
-5.86 | - | - | $ 621 M | Britain |
 |
BioVie
BIVI
|
-216.67 | $ 1.25 | -3.85 % | $ 9.06 M | USA |
 |
Kinnate Biopharma
KNTE
|
-76.05 | - | - | $ 123 M | USA |
 |
Mustang Bio
MBIO
|
-25.13 | $ 0.44 | 12.95 % | $ 2.16 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-66.38 | - | - | $ 7.29 B | USA |
 |
NexImmune
NEXI
|
-939.5 | - | 70.13 % | $ 4.12 M | USA |
 |
Codexis
CDXS
|
-82.6 | $ 1.0 | -9.91 % | $ 87.1 M | USA |
 |
Theravance Biopharma
TBPH
|
6.74 | $ 17.03 | 0.03 % | $ 857 M |  Cayman-islands |
 |
Compugen Ltd.
CGEN
|
23.38 | $ 2.06 | -3.72 % | $ 192 M |  Israel |
 |
IMV
IMV
|
-79.29 | - | - | $ 13.1 M | Canada |
 |
Sanofi
SNY
|
6.44 | $ 48.23 | 0.22 % | $ 58.9 B |  France |
 |
Karuna Therapeutics
KRTX
|
-39.45 | - | - | $ 12.2 B | USA |
 |
Chimerix
CMRX
|
-79.36 | - | - | $ 756 M | USA |
 |
Atreca
BCEL
|
-34.9 | - | -11.76 % | $ 5.79 M | USA |
 |
LogicBio Therapeutics
LOGC
|
-126.88 | - | - | $ 229 M | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
349.59 | $ 0.38 | -5.06 % | $ 4.68 B | Israel |
|
89bio
ETNB
|
-95.97 | - | - | $ 1.55 B | USA |
 |
Fusion Pharmaceuticals
FUSN
|
-44.6 | - | - | $ 1.41 B | Canada |
 |
Gritstone Oncology
GRTS
|
-269.28 | - | 0.42 % | $ 213 M | USA |
 |
Harpoon Therapeutics
HARP
|
-1265.51 | - | - | $ 763 M | USA |
 |
HOOKIPA Pharma
HOOK
|
-88.88 | - | -6.92 % | $ 79.4 M | USA |
 |
Guardion Health Sciences
GHSI
|
-53.23 | - | -0.31 % | $ 3.64 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
11.01 | - | - | $ 109 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Otonomy
OTIC
|
-90.38 | - | -1.96 % | $ 4.68 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
123.77 | - | 17.91 % | $ 11.1 M | USA |
 |
Seagen
SGEN
|
-21.46 | - | - | $ 42.2 B | USA |
|
Protara Therapeutics
TARA
|
-32.51 | $ 2.44 | -2.59 % | $ 105 M | USA |
 |
Baudax Bio
BXRX
|
73.86 | - | 0.59 % | $ 63 K | USA |
 |
ChemoCentryx
CCXI
|
-45.41 | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
-30.68 | - | - | $ 789 M | USA |